Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

Jingchao Liu, Zhangjian Huang, Wenhuan Ma, Sixun Peng, Yunman Li, Katrina M Miranda, Jide Tian, Yihua Zhang

Research output: Contribution to journalArticle

1 Scopus citations


Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM.

Original languageEnglish (US)
Pages (from-to)650-665
Number of pages16
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - Jan 15 2019



  • Ferulic acid
  • Glucose intolerance
  • Nitric oxide
  • Rosiglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this